Samrat Pharmachem Hits New 52-Week Low at Rs. 270.3

Samrat Pharmachem has reached a significant milestone by touching its 52-week low of Rs. 270.3 today, November 14, 2025. This marks a notable decline for the microcap pharmaceutical company, which has seen its stock price decrease by 41.88% over the past year, contrasting sharply with the Sensex's performance of 8.52% during the same period.
The stock has underperformed its sector, falling by 1.05% today alone, and has experienced a consecutive decline over the last two days, resulting in a total drop of 2.14%. Currently, Samrat Pharmachem is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained downward trend.

Despite the challenges reflected in its stock performance, the company has shown some resilience with a return on capital employed (ROCE) of 11.8% and an attractive valuation with a 1.1 enterprise value to capital employed ratio. Additionally, foreign institutional investors (FIIs) have increased their holdings to 3.24% this quarter, suggesting some level of confidence in the company's long-term prospects.